PTOV1

Summary

PTOV1 (PTOV1 extended AT-hook containing adaptor protein, HGNC:9632) is a protein-coding gene on chromosome 19q13.33, encoding Prostate tumor-overexpressed gene 1 protein (Q86YD1). May activate transcription.

This gene encodes a protein that was found to be overexpressed in prostate adenocarcinomas. The encoded protein was found to interact with the lipid raft protein flotillin-1 and shuttle it from the cytoplasm to the nucleus in a cell cycle dependent manner. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 53635 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 114 total
• MANE Select transcript: NM_001394010

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9632
Approved symbol	PTOV1
Name	PTOV1 extended AT-hook containing adaptor protein
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000104960
Ensembl biotype	protein_coding
OMIM	610195
Entrez	53635

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 9 protein_coding, 6 retained_intron, 5 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000391842, ENST00000594151, ENST00000594165, ENST00000594640, ENST00000595934, ENST00000596095, ENST00000596424, ENST00000597730, ENST00000597793, ENST00000598325, ENST00000598632, ENST00000599732, ENST00000600105, ENST00000600603, ENST00000600793, ENST00000601093, ENST00000601501, ENST00000601612, ENST00000601638, ENST00000601675, ENST00000602040

RefSeq mRNA: 9 — MANE Select: NM_001394010 NM_001305105, NM_001305108, NM_001364745, NM_001364747, NM_001364748, NM_001364749, NM_001364750, NM_001394010, NM_017432

CCDS: CCDS12782, CCDS82379, CCDS92668

Canonical transcript exons

ENST00000391842 — 12 exons

Exon	Start	End
ENSE00001509862	49851159	49851499
ENSE00003460400	49860268	49860742
ENSE00003475940	49854831	49854888
ENSE00003495166	49857904	49857977
ENSE00003526811	49856975	49857130
ENSE00003627229	49859986	49860183
ENSE00003647372	49854652	49854734
ENSE00003650615	49854970	49855077
ENSE00003668248	49858549	49858653
ENSE00003683118	49858057	49858114
ENSE00003689453	49854406	49854543
ENSE00003785359	49857693	49857782

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 99.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 80.9311 / max 362.9212, expressed in 1819 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177077	31.9843	1811
177078	31.8962	1808
177076	5.1081	1733
177079	4.2124	1485
177075	3.6386	1462
177074	1.6920	928
177085	1.1074	479
177080	0.8808	379
177086	0.2005	91
177082	0.0817	12

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	99.31	gold quality
ventricular zone	UBERON:0003053	99.30	gold quality
cortical plate	UBERON:0005343	99.29	gold quality
right uterine tube	UBERON:0001302	99.19	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.16	gold quality
adenohypophysis	UBERON:0002196	99.15	gold quality
cerebellar hemisphere	UBERON:0002245	99.10	gold quality
right testis	UBERON:0004534	99.10	gold quality
cerebellar cortex	UBERON:0002129	99.06	gold quality
left testis	UBERON:0004533	99.05	gold quality
pituitary gland	UBERON:0000007	99.00	gold quality
right adrenal gland	UBERON:0001233	98.98	gold quality
right adrenal gland cortex	UBERON:0035827	98.90	gold quality
left adrenal gland cortex	UBERON:0035825	98.85	gold quality
left adrenal gland	UBERON:0001234	98.83	gold quality
left ovary	UBERON:0002119	98.78	gold quality
right lobe of thyroid gland	UBERON:0001119	98.76	gold quality
right ovary	UBERON:0002118	98.74	gold quality
adrenal cortex	UBERON:0001235	98.68	gold quality
left lobe of thyroid gland	UBERON:0001120	98.62	gold quality
endocervix	UBERON:0000458	98.55	gold quality
right frontal lobe	UBERON:0002810	98.52	gold quality
cerebellum	UBERON:0002037	98.48	gold quality
adrenal gland	UBERON:0002369	98.39	gold quality
body of uterus	UBERON:0009853	98.32	gold quality
apex of heart	UBERON:0002098	98.29	gold quality
stromal cell of endometrium	CL:0002255	98.24	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.23	gold quality
left uterine tube	UBERON:0001303	98.18	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.17	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.97

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): JUN, RARA

miRNA regulators (miRDB)

14 targeting PTOV1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-6810-5P	98.29	66.21	975
HSA-MIR-6801-3P	98.04	64.64	805
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-450A-2-3P	97.91	67.56	1459
HSA-MIR-1285-3P	97.72	67.02	1932
HSA-MIR-5189-5P	97.72	66.96	1814
HSA-MIR-612	97.26	65.95	1597
HSA-MIR-6860	97.21	66.31	1656
HSA-MIR-6782-5P	96.45	64.42	612

Literature-anchored findings (GeneRIF, showing 21)

• This protein, overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. (PMID:12598323)
• PTOV1 assists flotillin-1 in its translocation to the nucleus and both proteins are required for cell proliferation. (PMID:15713644)
• PTOV1 is overexpressed in high-grade prostatic intraepithelial neoplasia associated with cancer and is a potential marker for studying the carcinogenesis and progression of prostate cancer. (PMID:18451224)
• MED25 and PTOV1 differentially modulate retinoic acid sensitivity in cancer cells depending on their expression levels. (PMID:21110951)
• PTOV1 expression is associated to more aggressive human carcinomas and more significantly to bladder carcinomas suggesting that this protein is a potential new marker of aggressive disease in the latter tumors. (PMID:21181414)
• alpha-Methyl-CoA racemase can be considered a more accurate marker than PTOV1 in the identification of high-grade prostatic intraepithelial neoplasia (HGPIN) and of prostate cancer. (PMID:22507319)
• RA-induced cancer cell cytotoxicity was significantly impaired by Zyxin or PTOV1. Overall, our findings suggest that Zyxin and PTOV1 should be considered as critical determinants in cancer therapy with retinoids (PMID:23321499)
• In prostate tumors, the overexpression of PTOV1 was associated with decreased expression of HEY1 and HES1, and this correlation was significant in metastatic lesions. (PMID:24684754)
• The study showed that PTOV1 is upregulated in breast cancer cell lines and clinical samples, and its expression was positively associated with progression and aggressiveness of breast cancer, suggesting that PTOV1 could serve as an independent prognostic marker. (PMID:24947166)
• PTOV1 protein abnormal expression might contribute to the malignant progression of epithelial ovarian cancer. (PMID:25270739)
• Our study demonstrated that PTOV1 overexpression is correlated with increased aggressiveness of hepatocellular carcinoma and could be a prognostic biomarker for patients with HCC (PMID:25634174)
• PTOV1 overexpression is associated with poor survival outcomes of nasopharyngeal carcinoma patients. (PMID:26305455)
• High PTOV1 expression was associated with invasive urothelial carcinoma. (PMID:26746655)
• The combination of PTOV1 expression level and HPV status provides more prognostic information compared with HPV status alone in early-stage human laryngeal squamous cell carcinoma. (PMID:26992242)
• All the study samples showed a considerable decrease in PTOV1 expression in prostate cancer and HGPIN compared to morphologically normal glands. (PMID:27804940)
• Studies indicate that the number of binding partners and associated cellular functions has increased and helped to identify prostate-tumor-overexpressed-1 (PTOV1) as regulator of gene expression at transcription and translation levels. (PMID:28029646)
• this study takes the lead to demonstrate that the overexpressed PTOV1 plays a vital role in the tumorigenesis and progression of esophageal squamous cell carcinoma, and it is potentially a valuable prognostic predicator and new chemotherapeutic target for esophageal squamous cell carcinoma (PMID:28651486)
• PTOV1 interaction with translation complexes and its direct binding to ALDH1A1 and CCNG2 promoters found here reveal the PTOV1 capacity to modulate the expression of critical genes at multiple levels in aggressive cancers. (PMID:30922918)
• the acquisition of resistance in laryngeal cancer seems to be related to PTOV1 (PMID:31050705)
• PTOV1 and PIN1 interact and exert oncogenic role in MDA-MB-231 cells by sharing the similar expression profile at transcriptional and translational level which can be a promising hub for therapeutic target. (PMID:31083670)
• this study revealed PTOV1 as a poor prognosis factor for NSCLC patients, and targeting PTOV1 can be a strategy to increase chemosensitivity in NSCLC. (PMID:31387622)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	med25	ENSDARG00000038005
mus_musculus	Ptov1	ENSMUSG00000038502
rattus_norvegicus	Ptov1	ENSRNOG00000020358
drosophila_melanogaster	MED25	FBGN0038760
drosophila_melanogaster	CG13609	FBGN0039170

Paralogs (1): MED25 (ENSG00000104973)

Protein

Protein identifiers

Prostate tumor-overexpressed gene 1 protein — Q86YD1 (reviewed: Q86YD1)

Alternative names: Activator interaction domain-containing protein 2

All UniProt accessions (8): A0A0C4DGR2, Q86YD1, M0QX53, M0QY25, M0QYH6, M0QYH7, M0QYQ4, M0QZB9

UniProt curated annotations — full annotation on UniProt →

Function. May activate transcription. Required for nuclear translocation of FLOT1. Promotes cell proliferation.

Subunit / interactions. May interact with CREBBP. Interacts with FLOT1.

Subcellular location. Cytoplasm. Nucleus. Cell membrane. Perinuclear region.

Tissue specificity. Expressed in brain, heart, kidney, liver, placenta, skeletal muscle and small intestine.

Post-translational modifications. Ubiquitinated by the CRL2(KLHDC2) complex, which recognizes the diglycine (Gly-Gly) at the C-terminus, leading to its degradation. Ubiquitinated by the CRL2(APPBP2) complex, which recognizes the Arg-Xaa-Xaa-Gly sequence at the C-terminus, leading to its degradation.

Induction. By testosterone.

Similarity. Belongs to the Mediator complex subunit 25 family. PTOV1 subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q86YD1-1	1	yes
Q86YD1-2	2
Q86YD1-3	3

RefSeq proteins (9): NP_001292034, NP_001292037, NP_001351674, NP_001351676, NP_001351677, NP_001351678, NP_001351679, NP_001380939, NP_059128 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR021394	Med25_PTOV	Domain
IPR038196	Med25_PTOV_sf	Homologous_superfamily

Pfam: PF11232

UniProt features (10 total): splice variant 4, region of interest 2, compositionally biased region 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86YD1-F1	68.43	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 53

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 161 (showing top): PAL_PRMT5_TARGETS_UP, ENK_UV_RESPONSE_KERATINOCYTE_UP, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, ONKEN_UVEAL_MELANOMA_UP, TGCTGAY_UNKNOWN, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, E4F1_Q6, DANG_BOUND_BY_MYC, TTCNRGNNNNTTC_HSF_Q6, TGGAAA_NFAT_Q4_01, CP2_01, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, SANSOM_APC_TARGETS_REQUIRE_MYC, GARY_CD5_TARGETS_UP

GO Biological Process (1): positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (0):

GO Cellular Component (7): nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), nucleus (GO:0005634), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
nuclear lumen	1
protein-containing complex	1
membrane	1
cell periphery	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

676 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTOV1	FLOT1	O75955	891
PTOV1	FLOT2	Q14254	768
PTOV1	MED6	O75586	686
PTOV1	SYN3	O14994	586
PTOV1	SYN2	Q92777	554
PTOV1	CAMK2G	Q13555	524
PTOV1	SYN1	P17600	490
PTOV1	ZNF395	Q9H8N7	473
PTOV1	NCOR2	Q9Y618	470
PTOV1	HDAC4	P56524	459
PTOV1	HDAC6	Q9UBN7	446
PTOV1	CAV1	Q03135	430
PTOV1	VWF	P04275	425
PTOV1	CREBBP	Q92793	408
PTOV1	AHSA1	O95433	400

IntAct

68 interactions, top by confidence:

A	B	Type	Score
CCM2	KRIT1	psi-mi:“MI:0914”(association)	0.960
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
CDCA4	PPP2R1A	psi-mi:“MI:0914”(association)	0.790
BECN1	ZWINT	psi-mi:“MI:0914”(association)	0.750
KLHDC2	CUL2	psi-mi:“MI:0914”(association)	0.730
YWHAH	FAM83G	psi-mi:“MI:0914”(association)	0.710
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
DNAAF8	CCDC85C	psi-mi:“MI:0914”(association)	0.530
KLHDC2	PFDN1	psi-mi:“MI:0914”(association)	0.530
PEX19	FAM20B	psi-mi:“MI:0914”(association)	0.530
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
N	NOP56	psi-mi:“MI:0914”(association)	0.530
YWHAZ	SHTN1	psi-mi:“MI:0914”(association)	0.530
ZNRD2	MYO9A	psi-mi:“MI:0914”(association)	0.530
PTGES3	AIP	psi-mi:“MI:0914”(association)	0.530
FOXJ1	PEX14	psi-mi:“MI:0914”(association)	0.530
PEX19	MYO1D	psi-mi:“MI:0914”(association)	0.530
NEFM	VWA8	psi-mi:“MI:0914”(association)	0.530
ZNRD2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
YWHAQ	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
PTOV1	SFN	psi-mi:“MI:0915”(physical association)	0.400
PTOV1	CCR4	psi-mi:“MI:0915”(physical association)	0.370
MAPK6		psi-mi:“MI:0914”(association)	0.350
RIPK4	VWA8	psi-mi:“MI:0914”(association)	0.350
CUL2	ANXA2P2	psi-mi:“MI:0914”(association)	0.350
YWHAG	C1orf226	psi-mi:“MI:0914”(association)	0.350

BioGRID (100): PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-Western), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), HDAC1 (Affinity Capture-MS), XYLT2 (Affinity Capture-MS), RTCB (Affinity Capture-MS), MTA2 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), PTOV1 (Affinity Capture-MS)

ESM2 similar proteins: A1L1K1, A2ARM1, A2AVJ5, A4IFC9, A7E305, G5EGQ2, O08653, O36006, O43435, O46080, O95343, P13481, P28702, P28704, P56423, P56424, P56645, P61260, P97499, Q02556, Q07820, Q2NL16, Q32N92, Q5E9R0, Q5REG4, Q5SQI0, Q5TJF7, Q5U2W6, Q5U2Y1, Q61010, Q62233, Q6MZQ0, Q80V91, Q86Y01, Q86YD1, Q8AW93, Q8BIG4, Q8HYS5, Q8N9I9, Q91VU8

Diamond homologs: A0A3Q7JC00, A2VE44, A4IFC9, A4IHD9, Q5U2W6, Q6GP15, Q6PEH8, Q71SY5, Q86YD1, Q8VCB2, Q91VU8, Q9VCB1, Q9VDR1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
HUWE1	“down-regulates quantity”	PTOV1	ubiquitination
SGK3	“down-regulates quantity by destabilization”	PTOV1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 84 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	89.6×	5e-09
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	79.0×	8e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	79.0×	8e-09
Activation of BH3-only proteins	6	58.4×	5e-08
RHO GTPases activate PKNs	6	37.3×	5e-07
Intrinsic Pathway for Apoptosis	6	34.5×	8e-07
FOXO-mediated transcription	5	32.9×	1e-05
Apoptosis	8	26.3×	5e-08

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	25.4×	8e-04
intracellular protein localization	7	10.2×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

114 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2543 predictions. Top by Δscore:

Variant	Effect	Δscore
19:49854399:A:AG	acceptor_gain	1.0000
19:49854399:ATT:A	acceptor_gain	1.0000
19:49854400:T:G	acceptor_gain	1.0000
19:49854401:TGCA:T	acceptor_loss	1.0000
19:49854402:GCA:G	acceptor_loss	1.0000
19:49854403:CA:C	acceptor_loss	1.0000
19:49854404:AG:A	acceptor_gain	1.0000
19:49854405:GG:G	acceptor_gain	1.0000
19:49854405:GGA:G	acceptor_gain	1.0000
19:49854405:GGAA:G	acceptor_gain	1.0000
19:49854540:GGAG:G	donor_gain	1.0000
19:49854541:GAG:G	donor_gain	1.0000
19:49854541:GAGG:G	donor_gain	1.0000
19:49854541:GAGGT:G	donor_loss	1.0000
19:49854544:G:GG	donor_gain	1.0000
19:49854544:GTGA:G	donor_loss	1.0000
19:49854545:T:G	donor_loss	1.0000
19:49854647:CACA:C	acceptor_loss	1.0000
19:49854648:ACAG:A	acceptor_loss	1.0000
19:49854650:A:AG	acceptor_gain	1.0000
19:49854650:A:C	acceptor_loss	1.0000
19:49854651:G:GG	acceptor_gain	1.0000
19:49854651:GA:G	acceptor_gain	1.0000
19:49854651:GAA:G	acceptor_gain	1.0000
19:49854651:GAAGC:G	acceptor_gain	1.0000
19:49854730:AACCT:A	donor_gain	1.0000
19:49854731:ACCT:A	donor_gain	1.0000
19:49854732:CCT:C	donor_gain	1.0000
19:49854733:CT:C	donor_gain	1.0000
19:49854733:CTGT:C	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000047569 (19:49856348 C>A), RS1000149564 (19:49848816 G>A), RS1000276473 (19:49852325 C>A,T), RS1000377580 (19:49853346 G>A), RS1000841885 (19:49858656 G>A,C,T), RS1000978229 (19:49852268 C>A,T), RS1001009670 (19:49850851 T>A,C), RS1001119999 (19:49855396 G>T), RS1001496833 (19:49858847 G>A,C), RS1001800924 (19:49852033 G>A), RS1001842698 (19:49858929 C>T), RS1001975253 (19:49858820 A>G), RS1002340336 (19:49854800 G>A), RS1002392275 (19:49851504 GC>G,GCC), RS1002399157 (19:49860990 C>T)

Disease associations

OMIM: gene MIM:610195 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): long QT syndrome (MONDO:0002442)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, increases abundance, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
salinomycin	decreases expression	1
beta-lapachone	decreases expression	1
arsenite	increases methylation	1
sodium arsenite	increases expression	1
ICG 001	decreases expression	1
bisphenol S	decreases methylation	1
MT19c compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Vorinostat	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Caffeine	decreases phosphorylation	1
Methotrexate	affects response to substance	1
Plant Extracts	affects cotreatment, decreases expression	1
Selenium	increases expression	1
Thimerosal	decreases expression	1
Thiram	decreases expression	1
Tretinoin	increases expression	1
Metribolone	increases expression	1
Aflatoxin B1	decreases expression	1
Antirheumatic Agents	increases expression	1
Palmitic Acid	decreases expression	1
Genistein	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea